Effects of intestinal microbial-elaborated butyrate on oncogenic signaling pathways

Nutrients

Volumn 11, Issue 5, 2019, Pages

  Chen, Jiezhong ^a   Zhao, Kong Nan ^b   Vitetta, Luis ^a,c  

^a Medlab   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Butyrate; Cellular signaling; Intestinal microbiota; Short chain fatty acids

Indexed keywords

AZOXYMETHANE; BUTYRIC ACID; CASPASE 10; CASPASE 3; CASPASE 8; CISPLATIN; CYCLIN D1; CYTOCHROME C; DOXORUBICIN; DYNAMIN I; ETOPOSIDE; FAS LIGAND; GEMCITABINE; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; IRINOTECAN; PROTEIN P53; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAT3 PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; URSODEOXYCHOLIC ACID; UVOMORULIN; VASCULOTROPIN; BUTYRIC ACID DERIVATIVE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLON ADENOMA; COLON CANCER; COLORECTAL CANCER; CYTOTOXICITY; DNA DAMAGE; DNA FRAGMENTATION; EWING SARCOMA; GENOMIC INSTABILITY; HCT 116 CELL LINE; HUMAN; INTESTINE FLORA; POLYPOSIS; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SPODOPTERA FRUGIPERDA; STOMACH CANCER; SW480 CELL LINE; WNT SIGNALING; DIETARY FIBER; GENE EXPRESSION REGULATION; METABOLISM; ONCOGENE; PHYSIOLOGY;

BUTYRATES; DIETARY FIBER; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION REGULATION; HUMANS; ONCOGENES;

EID: 85065799863     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu11051026     Document Type: Review

References (210)

1. Kundu, P.; Blacher, E.; Elinav, E.; Pettersson, S. Our Gut Microbiome: The Evolving Inner Self. Cell 2017, 171, 1481-1493.
2. Davenport, E.R.; Sanders, J.G.; Song, S.J.; Amato, K.R.; Clark, A.G.; Knight, R. The human microbiome in evolution. BMC Biol. 2017, 15, 127.
3. Maniar, K.; Moideen, A.; Mittal, A.; Patil, A.; Chakrabarti, A.; Banerjee, D. A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug? Pharm. Res. 2017, 117, 103-128.
4. Vipperla, K.; O’Keefe, S.J. Diet, microbiota, and dysbiosis: A ‘recipe’ for colorectal cancer. Food Funct. 2016, 7, 1731-1740.
5. Moore, T.; Rodriguez, A.; Bakken, J.S. Fecal microbiota transplantation: A practical update for the infectious disease specialist. Clin. Infect. Dis. 2014, 58, 541-545.
6. Bultman, S.J. Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Mol. Nutr. Food Res. 2017, 61, 1500902.
7. Biragyn, A.; Ferrucci, L. Gut dysbiosis: A potential link between increased cancer risk in ageing and inflammaging. Lancet Oncol. 2018, 19, e295-e304.
8. Jacouton, E.; Chain, F.; Sokol, H.; Langella, P.; Bermudez-Humaran, L.G. Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Front Immunol. 2017, 8, 1553.
9. Ma, C.; Han, M.; Heinrich, B.; Fu, Q.; Zhang, Q.; Sandhu, M.; Agdashian, D.; Terabe, M.; Berzofsky, J.A.; Fako, V.; et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018, 360, 6391.
10. McQuade, J.L.; Daniel, C.R.; Helmink, B.A.; Wargo, J.A. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019, 20, e77-e91.
11. Gopalakrishnan, V.; Helmink, B.A.; Spencer, C.N.; Reuben, A.; Wargo, J.A. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell 2018, 33, 570-580.
12. Helmink, B.A.; Khan, M.A.W.; Hermann, A.; Gopalakrishnan, V.; Wargo, J.A. The microbiome, cancer, and cancer therapy. Nat. Med. 2019, 25, 377-388.
13. Sethi, V.; Vitiello, G.A.; Saxena, D.; Miller, G.; Dudeja, V. The role of the microbiome in immunologic development and its implication for pancreatic cancer immunotherapy. Gastroenterology 2019, 156, 2097-2115.
14. Li, W.; Deng, Y.; Chu, Q.; Zhang, P. Gut microbiome and cancer immunotherapy. Cancer Lett. 2019, 447, 41-47.
15. Gharaibeh, R.Z.; Jobin, C. Microbiota and cancer immunotherapy: In search of microbial signals. Gut 2018, 68, 385-388.
16. Tanoue, T.; Morita, S.; Plichta, D.R.; Skelly, A.N.; Suda, W.; Sugiura, Y.; Narushima, S.; Vlamakis, H.; Motoo, I.; Sugita, K.; et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 2019, 565, 600-605.
17. Matson, V.; Fessler, J.; Bao, R.; Chongsuwat, T.; Zha, Y.; Alegre, M.L.; Luke, J.J.; Gajewski, T.F. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018, 359, 104-108.
18. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.; Vicente, D.; Hoffman, K.; Wei, S.; et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018, 359, 97-103.
19. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillere, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018, 359, 91-97.
20. Gill, P.A.; van Zelm, M.C.; Muir, J.G.; Gibson, P.R. Review article: Short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment Pharm. Ther. 2018, 48, 15-34.
21. Bedford, A.; Gong, J. Implications of butyrate and its derivatives for gut health and animal production. Anim. Nutr. 2018, 4, 151-159.
22. Bach Knudsen, K.E.; Laerke, H.N.; Hedemann, M.S.; Nielsen, T.S.; Ingerslev, A.K.; Gundelund Nielsen, D.S.; Theil, P.K.; Purup, S.; Hald, S.; Schioldan, A.; et al. Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation. Nutrients 2018, 10, 1499.
23. Encarnacao, J.C.; Abrantes, A.M.; Pires, A.S.; Botelho, M.F. Revisit dietary fiber on colorectal cancer: Butyrate and its role on prevention and treatment. Cancer Metastasis Rev. 2015, 34, 465-478.
24. Waldecker, M.; Kautenburger, T.; Daumann, H.; Busch, C.; Schrenk, D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J. Nutr. Biochem. 2008, 19, 587-593.
25. Donohoe, D.R.; Holley, D.; Collins, L.B.; Montgomery, S.A.; Whitmore, A.C.; Hillhouse, A.; Curry, K.P.; Renner, S.W.; Greenwalt, A.; Ryan, E.; et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov. 2014, 4, 1387-1397.
26. Candido, E.P.; Reeves, R.; Davie, J.R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978, 14, 105-113.
27. Perrin, P.; Pierre, F.; Patry, Y.; Champ, M.; Berreur, M.; Pradal, G.; Bornet, F.; Meflah, K.; Menanteau, J. Only fibers promoting a stable butyrate producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 2001, 48, 53-61.
28. Clarke, J.M.; Topping, D.L.; Bird, A.R.; Young, G.P.; Cobiac, L. Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats. Carcinogenesis 2008, 29, 2190-2194.
29. Tian, Y.; Xu, Q.; Sun, L.; Ye, Y.; Ji, G. Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. J. Nutr. Biochem. 2018, 57, 103-109.
30. Bishehsari, F.; Engen, P.A.; Preite, N.Z.; Tuncil, Y.E.; Naqib, A.; Shaikh, M.; Rossi, M.; Wilber, S.; Green, S.J.; Hamaker, B.; et al. Dietary Fiber Treatment Corrects the Composition of Gut Microbiota, Promotes SCFA Production, and Suppresses Colon Carcinogenesis. Genes 2018, 9, 102.
31. Kim, Y.H.; Park, J.W.; Lee, J.Y.; Kwon, T.K. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004, 25, 1813-1820.
32. Fung, K.Y.; Brierley, G.V.; Henderson, S.; Hoffmann, P.; McColl, S.R.; Lockett, T.; Head, R.; Cosgrove, L. Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response. J. Proteome Res. 2011, 10, 1860-1869.
33. Han, R.; Sun, Q.; Wu, J.; Zheng, P.; Zhao, G. Sodium Butyrate Upregulates miR-203 Expression to Exert Anti-Proliferation Effect on Colorectal Cancer Cells. Cell Physiol. Biochem. 2016, 39, 1919-1929.
34. Yonezawa, T.; Kobayashi, Y.; Obara, Y. Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line. Cell. Signal. 2007, 19, 185-193.
35. Pulliam, S.R.; Pellom, S.T., Jr.; Shanker, A.; Adunyah, S.E. Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis. Cytokine 2016, 84, 74-87.
36. Mrkvicova, A.; Chmelarova, M.; Peterova, E.; Havelek, R.; Baranova, I.; Kazimirova, P.; Rudolf, E.; Rezacova, M. The effect of sodium butyrate and cisplatin on expression of EMT markers. PLoS ONE 2019, 14, e0210889.
37. Cheriyath, V.; Kuhns, M.A.; Kalaycio, M.E.; Borden, E.C. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: Cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br. J. Cancer 2011, 104, 957-967.
38. Yu, M.; Kong, H.; Zhao, Y.; Sun, X.; Zheng, Z.; Yang, C.; Zhu, Y. Enhancement of adriamycin cytotoxicity by sodium butyrate involves hTERT downmodulation-mediated apoptosis in human uterine cancer cells. Mol. Carcinog. 2014, 53, 505-513.
39. Dos Santos, M.P.; de Farias, C.B.; Roesler, R.; Brunetto, A.L.; Abujamra, A.L. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: A paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma. Oncol. Rep. 2014, 31, 955-968.
40. Encarnacao, J.C.; Pires, A.S.; Amaral, R.A.; Goncalves, T.J.; Laranjo, M.; Casalta-Lopes, J.E.; Goncalves, A.C.; Sarmento-Ribeiro, A.B.; Abrantes, A.M.; Botelho, M.F. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J. Nutr. Biochem. 2018, 56, 183-192.
41. Wawruszak, A.; Kalafut, J.; Okon, E.; Czapinski, J.; Halasa, M.; Przybyszewska, A.; Miziak, P.; Okla, K.; Rivero-Muller, A.; Stepulak, A. Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells. Cancers 2019, 11, 148.
42. Lernoux, M.; Schnekenburger, M.; Dicato, M.; Diederich, M. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharm. Res. 2018, 129, 337-356.
43. Tsilimigras, D.I.; Ntanasis-Stathopoulos, I.; Moris, D.; Spartalis, E.; Pawlik, T.M. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective. Surg. Oncol. 2018, 27, 611-618.
44. Eckschlager, T.; Plch, J.; Stiborova, M.; Hrabeta, J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int. J. Mol. Sci. 2017, 18, 1414.
45. Cuisset, L.; Tichonicky, L.; Delpech, M. A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate. Biochem. Biophys. Commun. 1998, 246, 760-764.
46. Donohoe, D.R.; Collins, L.B.; Wali, A.; Bigler, R.; Sun, W.; Bultman, S.J. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell 2012, 48, 612-626.
47. Gao, S.M.; Chen, C.Q.; Wang, L.Y.; Hong, L.L.; Wu, J.B.; Dong, P.H.; Yu, F.J. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Exp. Hematol. 2013, 41, 261-270.
48. Ram, P.T.; Iyengar, R. G protein coupled receptor signaling through the Src and Stat3 pathway: Role in proliferation and transformation. Oncogene 2001, 20, 1601-1606.
49. Silva, C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004, 23, 8017-8023.
50. Xu, Q.; Briggs, J.; Park, S.; Niu, G.; Kortylewski, M.; Zhang, S.; Gritsko, T.; Turkson, J.; Kay, H.; Semenza, G.; et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24, 5552-5560.
51. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.
52. Klampfer, L.; Huang, J.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 2003, 1, 855-862.
53. Shin, H.; Kim, J.H.; Lee, Y.S.; Lee, Y.C. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: Induction of promoter demethylation and histone modification causing inhibition of Wnt signaling. Int. J. Oncol. 2012, 40, 1533-1542.
54. Kaya, M.; Wada, T.; Akatsuka, T.; Kawaguchi, S.; Nagoya, S.; Shindoh, M.; Higashino, F.; Mezawa, F.; Okada, F.; Ishii, S. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res. 2000, 6, 572-577.
55. Apte, R.S.; Chen, D.S.; Ferrara, N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell 2019, 176, 1248-1264.
56. Yu, D.C.; Waby, J.S.; Chirakkal, H.; Staton, C.A.; Corfe, B.M. Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation. Mol. Cancer 2010, 9, 276.
57. Sawa, H.; Murakami, H.; Ohshima, Y.; Murakami, M.; Yamazaki, I.; Tamura, Y.; Mima, T.; Satone, A.; Ide, W.; Hashimoto, I.; et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 2002, 19, 77-81.
58. Kaiser, M.; Zavrski, I.; Sterz, J.; Jakob, C.; Fleissner, C.; Kloetzel, P.M.; Sezer, O.; Heider, U. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006, 91, 248-251.
59. Pellizzaro, C.; Coradini, D.; Daidone, M.G. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 2002, 23, 735-740.
60. Kim, S.H.; Kim, K.W.; Jeong, J.W. Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression. Oncol. Rep. 2007, 17, 793-797.
61. Takahashi, T.; Yamaguchi, S.; Chida, K.; Shibuya, M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. Embo J. 2001, 20, 2768-2778.
62. Holmqvist, K.; Cross, M.J.; Rolny, C.; Hagerkvist, R.; Rahimi, N.; Matsumoto, T.; Claesson-Welsh, L.; Welsh, M. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J. Biol. Chem. 2004, 279, 22267-22275.
63. Chen, J. Multiple signal pathways in obesity-associated cancer. Obes. Rev. 2011, 12, 1063-1070.
64. Chen, J.; Elfiky, A.; Han, M.; Chen, C.; Saif, M.W. The role of Src in colon cancer and its therapeutic implications. Clin. Colorectal Cancer 2014, 13, 5-13.
65. Hanker, A.B.; Kaklamani, V.; Arteaga, C.L. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discov. 2019, 9, 482-491.
66. Corti, F.; Nichetti, F.; Raimondi, A.; Niger, M.; Prinzi, N.; Torchio, M.; Tamborini, E.; Perrone, F.; Pruneri, G.; Di Bartolomeo, M.; et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. Cancer Treat. Rev. 2019, 72, 45-55.
67. Santarpia, L.; Lippman, S.M.; El-Naggar, A.K. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin. Targets 2012, 16, 103-119.
68. Chen, J. Signaling pathways in HPV-associated cancers and therapeutic implications. Rev. Med. Virol. 2015, 25, 24-53.
69. Noh, K.H.; Kang, T.H.; Kim, J.H.; Pai, S.I.; Lin, K.Y.; Hung, C.F.; Wu, T.C.; Kim, T.W. Activation of Akt as a mechanism for tumor immune evasion. Mol. Ther. 2009, 17, 439-447.
70. Chen, J.; Jiang, C.C.; Jin, L.; Zhang, X.D. Regulation of PD-L1, a novel role of pro-survival signaling in cancer. Ann. Oncol. 2016, 27, 409-416.
71. Minami, A.; Nakanishi, A.; Ogura, Y.; Kitagishi, Y.; Matsuda, S. Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Front. Oncol. 2014, 4, 318.
72. Guttmann-Raviv, N.; Kessler, O.; Shraga-Heled, N.; Lange, T.; Herzog, Y.; Neufeld, G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 2006, 231, 1-11.
73. Matkar, P.N.; Jong, E.D.; Ariyagunarajah, R.; Prud’homme, G.J.; Singh, K.K.; Leong-Poi, H. Jack of many trades: Multifaceted role of neuropilins in pancreatic cancer. Cancer Med. 2018, 7, 5036-5046.
74. Hu, C.; Jiang, X. Role of NRP-1 in VEGF-VEGFR2-Independent Tumorigenesis. Target Oncol. 2016, 11, 501-505.
75. Li, Q.; Ding, C.; Meng, T.; Lu, W.; Liu, W.; Hao, H.; Cao, L. Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner. J. Pharm. Sci. 2017, 135, 148-155.
76. Bai, Z.; Zhang, Z.; Ye, Y.; Wang, S. Sodium butyrate induces differentiation of gastric cancer cells to intestinal cells via the PTEN/phosphoinositide 3-kinase pathway. Cell Biol. Int. 2010, 34, 1141-1145.
77. Chen, G.; Ran, X.; Li, B.; Li, Y.; He, D.; Huang, B.; Fu, S.; Liu, J.; Wang, W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. eBioMedicine 2018, 30, 317-325.
78. Stefanikova, A.; Klikova, K.; Hatok, J.; Racay, P. ABT-737 accelerates butyrate-induced death of HL-60 cells. Involvement of mitochondrial apoptosis pathway. Gen. Physiol. Biophys. 2013, 32, 505-516.
79. Luna-Vargas, M.P.A.; Chipuk, J.E. Physiological and Pharmacological Control of BAK, BAX, and Beyond. Trends Cell Biol. 2016, 26, 906-917.
80. Singh, R.; Letai, A.; Sarosiek, K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell. Biol. 2019, 20, 175-193.
81. Richardson, A.; Kaye, S.B. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr. Mol. Pharmacol. 2008, 1, 244-254.
82. Delbridge, A.R.; Grabow, S.; Strasser, A.; Vaux, D.L. Thirty years of BCL-2, translating cell death discoveries into novel cancer therapies. Nat. Rev. Cancer 2016, 16, 99-109.
83. Yeom, J.-H.; Ryou, S.-M.; Won, M.; Park, M.; Bae, J.; Lee, K. Inhibition of Xenograft Tumor Growth by Gold Nanoparticle-DNA Oligonucleotide Conjugates-Assisted Delivery of BAX mRNA. PLoS ONE 2013, 8, e75369.
84. Kumar, J.S.; Suman, S.; Chandna, S. Radioresistant Sf9 insect cells readily undergo an intrinsic mode of apoptosis in response to histone deacetylase (HDAC) inhibition. Mol. Cell Biochem. 2018, 444, 207-218.
85. Mu, D.; Gao, Z.; Guo, H.; Zhou, G.; Sun, B. Sodium butyrate induces growth inhibition and apoptosis in human prostate cancer DU145 cells by up-regulation of the expression of annexin A1. PLoS ONE 2013, 8, e74922.
86. Ruemmele, F.M.; Schwartz, S.; Seidman, E.G.; Dionne, S.; Levy, E.; Lentze, M.J. Butyrate induced Caco-2 cell apoptosis is mediated via the mitochondrial pathway. Gut 2003, 52, 94-100.
87. Zhang, Y.; Zhou, L.; Bao, Y.L.; Wu, Y.; Yu, C.L.; Huang, Y.X.; Sun, Y.; Zheng, L.H.; Li, Y.X. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. Chem. Biol. Interact. 2010, 185, 174-181.
88. Cho, S.D.; Ahn, N.S.; Jung, J.W.; Yang, S.R.; Park, J.S.; Lee, Y.S.; Jo, E.H.; Hwang, J.W.; Lii, J.; Kang, K.S. Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur. J. Cancer Prev. 2006, 15, 57-63.
89. Choi, Y.H. Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity. Int. J. Oncol. 2006, 29, 1207-1213.
90. Schwab, M.; Reynders, V.; Shastri, Y.; Loitsch, S.; Stein, J.; Schroder, O. Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol. Immunol. 2007, 44, 2107-2114.
91. Xie, C.; Wu, B.; Chen, B.; Shi, Q.; Guo, J.; Fan, Z.; Huang, Y. Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Oncotargets Ther. 2016, 9, 4005-4013.
92. Tailor, D.; Hahm, E.R.; Kale, R.K.; Singh, S.V.; Singh, R.P. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion 2014, 16, 55-64.
93. Kryukov, F.; Dementyeva, E.; Kubiczkova, L.; Jarkovsky, J.; Brozova, L.; Petrik, J.; Nemec, P.; Sevcikova, S.; Minarik, J.; Stefanikova, Z.; et al. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics 2013, 102, 243-249.
94. Chopin, V.; Toillon, R.A.; Jouy, N.; Le Bourhis, X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br. J. Pharm. 2002, 135, 79-86.
95. Derakhshan, A.; Chen, Z.; Van Waes, C. Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways. Clin. Cancer Res. 2017, 23, 1379-1387.
96. Ashkenazi, A. Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions. J. Clin. Investig. 2015, 125, 487-489.
97. Zimmerman, M.A.; Singh, N.; Martin, P.M.; Thangaraju, M.; Ganapathy, V.; Waller, J.L.; Shi, H.; Robertson, K.D.; Munn, D.H.; Liu, K. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Liver Physiol. 2012, 302, G1405-G1415.
98. Tummers, B.; Green, D.R. Caspase-8, regulating life and death. Immunol. Rev. 2017, 277, 76-89.
99. Pajak, B.; Orzechowski, A.; Gajkowska, B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv. Med. Sci. 2007, 52, 83-88.
100. Sun, S.; Li, W.; Zhang, H.; Zha, L.; Xue, Y.; Wu, X.; Zou, F. Requirement for store-operated calcium entry in sodium butyrate-induced apoptosis in human colon cancer cells. Biosci. Rep. 2012, 32, 83-90.
101. Singh, N.; Gurav, A.; Sivaprakasam, S.; Brady, E.; Padia, R.; Shi, H.; Thangaraju, M.; Prasad, P.D.; Manicassamy, S.; Munn, D.; et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014, 40, 128-139.
102. Cresci, G.A.; Thangaraju, M.; Mellinger, J.D.; Liu, K.; Ganapathy, V. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J. Gastrointest. Surg. 2010, 14, 449-461.
103. Thangaraju, M.; Cresci, G.A.; Liu, K.; Ananth, S.; Gnanaprakasam, J.P.; Browning, D.D.; Mellinger, J.D.; Smith, S.B.; Digby, G.J.; Lambert, N.; et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009, 69, 2826-2832.
104. Lin, H.V.; Frassetto, A.; Kowalik, E.J., Jr.; Nawrocki, A.R.; Lu, M.M.; Kosinski, J.R.; Hubert, J.A.; Szeto, D.; Yao, X.; Forrest, G.; et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 2012, 7, e35240.
105. Maslowski, K.M.; Vieira, A.T.; Ng, A.; Kranich, J.; Sierro, F.; Yu, D.; Schilter, H.C.; Rolph, M.S.; Mackay, F.; Artis, D.; et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461, 1282-1286.
106. Pan, P.; Oshima, K.; Huang, Y.W.; Agle, K.A.; Drobyski, W.R.; Chen, X.; Zhang, J.; Yearsley, M.M.; Yu, J.; Wang, L.S. Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int. J. Cancer 2018, 143, 886-896.
107. Zeng, H.; Taussig, D.P.; Cheng, W.H.; Johnson, L.K.; Hakkak, R. Butyrate Inhibits Cancerous HCT116 Colon Cell Proliferation but to a Lesser Extent in Noncancerous NCM460 Colon Cells. Nutrients 2017, 9, 25.
108. Tang, Y.; Chen, Y.; Jiang, H.; Robbins, G.T.; Nie, D. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int. J. Cancer 2011, 128, 847-856.
109. Fetisov, T.I.; Lesovaya, E.A.; Yakubovskaya, M.G.; Kirsanov, K.I.; Belitsky, G.A. Alterations in WNT Signaling in Leukemias. Biochemistry 2018, 83, 1448-1458.
110. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851.
111. Bienz, M.; Clevers, H. Linking colorectal cancer to Wnt signaling. Cell 2000, 103, 311-320.
112. Barker, N.; Clevers, H. Catenins, Wnt signaling and cancer. Bioessays 2000, 22, 961-965.
113. Bordonaro, M.; Lazarova, D. Amlexanox and UPF1 Modulate Wnt Signaling and Apoptosis in HCT-116 Colorectal Cancer Cells. J. Cancer 2019, 10, 287-292.
114. Wu, X.; Wu, Y.; He, L.; Wu, L.; Wang, X.; Liu, Z. Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer. J. Cancer 2018, 9, 2510-2517.
115. Lazarova, D.L.; Bordonaro, M. p300 Knockout Promotes Butyrate Resistance. J. Cancer 2017, 8, 3405-3409.
116. Emami, K.H.; Nguyen, C.; Ma, H.; Kim, D.H.; Jeong, K.W.; Eguchi, M.; Moon, R.T.; Teo, J.L.; Kim, H.Y.; Moon, S.; et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc. Natl. Acad. Sci. USA 2004, 101, 12682-12687.
117. Ma, H.; Nguyen, C.; Lee, K.S.; Kahn, M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005, 24, 3619-3631.
118. Zhao, Y.; Masiello, D.; McMillian, M.; Nguyen, C.; Wu, Y.; Melendez, E.; Smbatyan, G.; Kida, A.; He, Y.; Teo, J.; et al. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells. Oncogene 2016, 35, 3705-3717.
119. Manegold, P.; Lai, K.K.Y.; Wu, Y.; Teo, J.L.; Lenz, H.J.; Genyk, Y.S.; Pandol, S.J.; Wu, K.; Lin, D.P.; Chen, Y.; et al. Differentiation Therapy Targeting the beta-Catenin/CBP Interaction in Pancreatic Cancer. Cancers 2018, 10, 95.
120. Nishizuka, Y. Turnover of inositol phospholipids and signal transduction. Science 1984, 225, 1365-1370.
121. Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984, 308, 693-698.
122. Keenan, C.; Kelleher, D. Protein kinase C and the cytoskeleton. Cell Signal 1998, 10, 225-232.
123. Lampasso, J.D.; Chen, W.; Marzec, N. The expression profile of PKC isoforms during MC3T3-E1 differentiation. Int. J. Mol. Med 2006, 17, 1125-1131.
124. Newton, A.C. Protein kinase C as a tumor suppressor. Semin. Cancer Biol. 2018, 48, 18-26.
125. Callender, J.A.; Yang, Y.; Lorden, G.; Stephenson, N.L.; Jones, A.C.; Brognard, J.; Newton, A.C. Protein kinase Calpha gain-of-function variant in Alzheimer’s disease displays enhanced catalysis by a mechanism that evades down-regulation. Proc. Natl. Acad. Sci. USA 2018, 115, E5497-E5505.
126. Newton, A.C. Protein kinase, C. perfectly balanced. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 208-230.
127. Wu-Zhang, A.X.; Newton, A.C. Protein kinase C pharmacology: Refining the toolbox. Biochem. J. 2013, 452, 195-209.
128. Griner, E.M.; Kazanietz, M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 2007, 7, 281-294.
129. Fleming, A.K.; Storz, P. Protein kinase C isoforms in the normal pancreas and in pancreatic disease. Cell Signal 2017, 40, 1-9.
130. Choi, P.M.; Tchou-Wong, K.M.; Weinstein, I.B. Overexpression of protein kinase C in HT29 colon cancer cells causes growth inhibition and tumor suppression. Mol. Cell. Biol. 1990, 10, 4650-4657.
131. Rivero, J.A.; Adunyah, S.E. Sodium butyrate stimulates PKC activation and induces differential expression of certain PKC isoforms during erythroid differentiation. Biochem. Biophys. Res. Commun. 1998, 248, 664-668.
132. Rickard, K.L.; Gibson, P.R.; Young, G.P.; Phillips, W.A. Activation of protein kinase C augments butyrate-induced differentiation and turnover in human colonic epithelial cells in vitro. Carcinogenesis 1999, 20, 977-984.
133. Orchel, A.; Dzierzewicz, Z.; Parfiniewicz, B.; Weglarz, L.; Wilczok, T. Butyrate-induced differentiation of colon cancer cells is PKC and JNK dependent. Dig. Dis. Sci. 2005, 50, 490-498.
134. Kopp, R.; Fichter, M.; Assert, R.; Pfeiffer, A.F.; Classen, S. Butyrate-induced alterations of phosphoinositide metabolism, protein kinase C activity and reduced CD44 variant expression in HT-29 colon cancer cells. Int. J. Mol. Med. 2009, 23, 639-649.
135. Scharlau, D.; Borowicki, A.; Habermann, N.; Hofmann, T.; Klenow, S.; Miene, C.; Munjal, U.; Stein, K.; Glei, M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fiber. Mutat. Res. 2009, 682, 39-53.
136. McMillan, L.; Butcher, S.K.; Pongracz, J.; Lord, J.M. Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: Differential activation of PKC and MAP kinases. Br. J. Cancer 2003, 88, 748-753.
137. Souza, B.K.; da Costa Lopez, P.L.; Menegotto, P.R.; Vieira, I.A.; Kersting, N.; Abujamra, A.L.; Brunetto, A.T.; Brunetto, A.L.; Gregianin, L.; de Farias, C.; et al. Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. Mol. Neurobiol. 2018, 55, 7242-7258.
138. Williams, E.A.; Coxhead, J.M.; Mathers, J.C. Anti-cancer effects of butyrate: Use of micro-array technology to investigate mechanisms. Proc. Nutr. Soc. 2003, 62, 107-115.
139. Arpaia, N.; Campbell, C.; Fan, X.; Dikiy, S.; van der Veeken, J.; deRoos, P.; Liu, H.; Cross, J.R.; Pfeffer, K.; Coffer, P.; et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013, 504, 451-455.
140. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504, 446-450.
141. Nastasi, C.; Fredholm, S.; Willerslev-Olsen, A.; Hansen, M.; Bonefeld, C.M.; Geisler, C.; Andersen, M.H.; Odum, N.; Woetmann, A. Butyrate and propionate inhibit antigen-specific CD8(+) T cell activation by suppressing IL-12 production by antigen-presenting cells. Sci. Rep. 2017, 7, 14516.
142. Luceri, C.; Femia, A.P.; Fazi, M.; Di Martino, C.; Zolfanelli, F.; Dolara, P.; Tonelli, F. Effect of butyrate enemas on gene expression profiles and endoscopic/histopathological scores of diverted colorectal mucosa: A randomized trial. Dig. Liver Dis. 2016, 48, 27-33.
143. Miyachi, T.; Adachi, M.; Hinoda, Y.; Imai, K. Butyrate augments interferon-alpha-induced S phase accumulation and persistent tyrosine phosphorylation of cdc2 in K562 cells. Br. J. Cancer 1999, 79, 1018-1024.
144. Kovarik, J.J.; Holzl, M.A.; Hofer, J.; Waidhofer-Sollner, P.; Sobanov, Y.; Koeffel, R.; Saemann, M.D.; Mechtcheriakova, D.; Zlabinger, G.J. Eicosanoid modulation by the short-chain fatty acid n-butyrate in human monocytes. Immunology 2013, 139, 395-405.
145. Sauer, J.; Richter, K.K.; Pool-Zobel, B.L. Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J. Nutr. Biochem. 2007, 18, 736-745.
146. Schwab, J.M.; Chiang, N.; Arita, M.; Serhan, C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447, 869-874.
147. Sakamoto, K.; Maeda, S.; Hikiba, Y.; Nakagawa, H.; Hayakawa, Y.; Shibata, W.; Yanai, A.; Ogura, K.; Omata, M. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin. Cancer Res. 2009, 15, 2248-2258.
148. Chen, J.; Vitetta, L. Inflammation-Modulating Effect of Butyrate in the Prevention of Colon Cancer by Dietary Fiber. Clin. Color. Cancer 2018, 17, e541-e544.
149. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281-297.
150. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9, 775-789.
151. Nana-Sinkam, P.; Croce, C.M. MicroRNAs in diagnosis and prognosis in cancer: What does the future hold? Pharmacogenomics 2010, 11, 667-669.
152. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal Transduct. Target 2016, 1, 15004.
153. Farooqi, A.A.; Fuentes-Mattei, E.; Fayyaz, S.; Raj, P.; Goblirsch, M.; Poltronieri, P.; Calin, G.A. Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. Semin. Cancer Biol. 2019.
154. Misiewicz-Krzeminska, I.; Krzeminski, P.; Corchete, L.A.; Quwaider, D.; Rojas, E.A.; Herrero, A.B.; Gutierrez, N.C. Factors Regulating microRNA Expression and Function in Multiple Myeloma. Noncoding RNA 2019, 5, 9.
155. Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12, 847-865.
156. Garzon, R.; Calin, G.A.; Croce, C.M. MicroRNAs in Cancer. Annu. Rev. Med. 2009, 60, 167-179.
157. Iorio, M.V.; Croce, C.M. MicroRNAs in cancer: Small molecules with a huge impact. J. Clin. Oncol. 2009, 27, 5848-5856.
158. Hu, S.; Dong, T.S.; Dalal, S.R.; Wu, F.; Bissonnette, M.; Kwon, J.H.; Chang, E.B. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS ONE 2011, 6, e16221.
159. Xiong, Y.; Hannon, G.J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366, 701-704.
160. Zhang, H.; Xiong, Y.; Beach, D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol. Biol. Cell 1993, 4, 897-906.
161. Flores-Rozas, H.; Kelman, Z.; Dean, F.B.; Pan, Z.Q.; Harper, J.W.; Elledge, S.J.; O’Donnell, M.; Hurwitz, J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA 1994, 91, 8655-8659.
162. Huang, L.; Sowa, Y.; Sakai, T.; Pardee, A.B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 2000, 19, 5712-5719.
163. Fujii, R.; Osaka, E.; Sato, K.; Tokuhashi, Y. MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3. Cancer Genom. Proteom. 2019, 16, 71-79.
164. Xiao, X.; Cao, Y.; Chen, H. Profiling and characterization of microRNAs responding to sodium butyrate treatment in A549 cells. J. Cell Biochem. 2018, 119, 3563-3573.
165. Hu, S.; Liu, L.; Chang, E.B.; Wang, J.Y.; Raufman, J.P. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol. Cancer 2015, 14, 180.
166. Borriello, A.; Caldarelli, I.; Bencivenga, D.; Criscuolo, M.; Cucciolla, V.; Tramontano, A.; Oliva, A.; Perrotta, S.; Della Ragione, F. p57(Kip2) and cancer: Time for a critical appraisal. Mol. Cancer Res. 2011, 9, 1269-1284.
167. Kavanagh, E.; Joseph, B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim. Biophys. Acta 2011, 1816, 50-56.
168. Pant, K.; Yadav, A.K.; Gupta, P.; Islam, R.; Saraya, A.; Venugopal, S.K. Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. Redox Biol. 2017, 12, 340-349.
169. Shagisultanova, E.; Gaponova, A.V.; Gabbasov, R.; Nicolas, E.; Golemis, E.A. Preclinical and clinical studies of the NEDD9 scaffold protein in cancer and other diseases. Gene 2015, 567, 1-11.
170. Emran, A.A.; Chatterjee, A.; Rodger, E.J.; Tiffen, J.C.; Gallagher, S.J.; Eccles, M.R.; Hersey, P. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends Immunol. 2019, 40, 328-344.
171. Deaton, A.M.; Bird, A. CpG islands and the regulation of transcription. Genes Dev. 2011, 25, 1010-1022.
172. Jones, P.A.; Ohtani, H.; Chakravarthy, A.; De Carvalho, D.D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 2019, 19, 151-161.
173. Esteller, M. CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene 2002, 21, 5427-5440.
174. Zheng, Y.; Li, X.; Jiang, Y.; Xu, Y.; Song, B.; Zhou, Q.; Liang, X.; Yang, X. Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis. Medicine 2016, 95, e5433.
175. Liang, G.; Weisenberger, D.J. DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 2017, 12, 416-432.
176. Kumar, P.; Naumann, U.; Aigner, L.; Wischhusen, J.; Beier, C.P.; Beier, D. Impaired TGF-beta induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53. Am. J. Cancer Res. 2015, 5, 3436-3445.
177. Parker, M.I.; de Haan, J.B.; Gevers, W. DNA hypermethylation in sodium butyrate-treated WI-38 fibroblasts. J. Biol. Chem. 1986, 261, 2786-2790.
178. De Haan, J.B.; Gevers, W.; Parker, M.I. Effects of sodium butyrate on the synthesis and methylation of DNA in normal cells and their transformed counterparts. Cancer Res. 1986, 46, 713-716.
179. Tsung, A.J.; Guda, M.R.; Asuthkar, S.; Labak, C.M.; Purvis, I.J.; Lu, Y.; Jain, N.; Bach, S.E.; Prasad, D.V.R.; Velpula, K.K. Methylation regulates HEY1 expression in glioblastoma. Oncotarget 2017, 8, 44398-44409.
180. Kobayashi, M.; Mikami, D.; Uwada, J.; Yazawa, T.; Kamiyama, K.; Kimura, H.; Taniguchi, T.; Iwano, M. A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells. Oncotarget 2018, 9, 31342-31354.
181. Zhang, Z.; Nor, F.; Oh, M.; Cucco, C.; Shi, S.; Nor, J.E. Wnt/beta-Catenin Signaling Determines the Vasculogenic Fate of Postnatal Mesenchymal Stem Cells. Stem Cells 2016, 34, 1576-1587.
182. Blanc, E.; Goldschneider, D.; Douc-Rasy, S.; Benard, J.; Raguenez, G. Wnt-5a gene expression in malignant human neuroblasts. Cancer Lett. 2005, 228, 117-123.
183. Blanc, E.; Roux, G.L.; Benard, J.; Raguenez, G. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 2005, 24, 1277-1283.
184. Donohoe, D.R.; Curry, K.P.; Bultman, S.J. Microbial oncotarget: Bacterial-produced butyrate, chemoprevention and Warburg effect. Oncotarget 2013, 4, 182-183.
185. Sebastian, C.; Mostoslavsky, R. Untangling the fiber yarn: Butyrate feeds Warburg to suppress colorectal cancer. Cancer Discov. 2014, 4, 1368-1370.
186. Burgess, D.J. Metabolism: Warburg behind the butyrate paradox? Nat. Rev. Cancer 2012, 12, 798.
187. Han, A.; Bennett, N.; Ahmed, B.; Whelan, J.; Donohoe, D.R. Butyrate decreases its own oxidation in colorectal cancer cells through inhibition of histone deacetylases. Oncotarget 2018, 9, 27280-27292.
188. Han, A.; Bennett, N.; MacDonald, A.; Johnstone, M.; Whelan, J.; Donohoe, D.R. Cellular Metabolism and Dose Reveal Carnitine-Dependent and -Independent Mechanisms of Butyrate Oxidation in Colorectal Cancer Cells. J. Cell Physiol. 2016, 231, 1804-1813.
189. Andriamihaja, M.; Chaumontet, C.; Tome, D.; Blachier, F. Butyrate metabolism in human colon carcinoma cells: Implications concerning its growth-inhibitory effect. J. Cell Physiol. 2009, 218, 58-65.
190. Foglietta, F.; Serpe, L.; Canaparo, R.; Vivenza, N.; Riccio, G.; Imbalzano, E.; Gasco, P.; Zara, G.P. Modulation of butyrate anticancer activity by solid lipid nanoparticle delivery: An in vitro investigation on human breast cancer and leukemia cell lines. J. Pharm. Pharm. Sci. 2014, 17, 231-247.
191. Prabhakar, U.; Blakey, D.C.; Maeda, H.; Jain, R.K.; Sevick-Muraca, E.M.; Zamboni, W.; Farokhzad, O.C.; Barry, S.T.; Gabizon, A.; Grodzinski, P. Challenges and key considerations of the enhanced permeability and retention effect (EPR) for nanomedicine drug delivery in oncology. Cancer Res. 2013.
192. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54, 987-992.
193. Moghimi, S.M.; Hunter, A.C. Capture of stealth nanoparticles by the body’s defences. Crit. Rev. Drug Carr. Syst. 2001, 18, 527-550.
194. Minelli, R.; Serpe, L.; Pettazzoni, P.; Minero, V.; Barrera, G.; Gigliotti, C.; Mesturini, R.; Rosa, A.C.; Gasco, P.; Vivenza, N.; et al. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br. J. Pharm. 2012, 166, 587-601.
195. Minelli, R.; Occhipinti, S.; Gigliotti, C.L.; Barrera, G.; Gasco, P.; Conti, L.; Chiocchetti, A.; Zara, G.P.; Fantozzi, R.; Giovarelli, M.; et al. Solid lipid nanoparticles of cholesteryl butyrate inhibit the proliferation of cancer cells in vitro and in vivo models. Br. J. Pharm. 2013, 170, 233-244.
196. Saldanha, S.N.; Kala, R.; Tollefsbol, T.O. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp. Cell Res. 2014, 324, 40-53.
197. Jankun, J.; Selman, S.H.; Swiercz, R.; Skrzypczak-Jankun, E. Why drinking green tea could prevent cancer. Nature 1997, 387, 561.
198. Bradford, P.G.; Awad, A.B. Phytosterols as anticancer compounds. Mol. Nutr. Food Res. 2007, 51, 161-170.
199. Suganuma, M.; Ohkura, Y.; Okabe, S.; Fujiki, H. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J. Cancer Res. Clin. Oncol. 2001, 127, 69-72.
200. Orner, G.A.; Dashwood, W.M.; Blum, C.A.; Diaz, G.D.; Li, Q.; Dashwood, R.H. Suppression of tumorigenesis in the Apc(min) mouse: Down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003, 24, 263-267.
201. Ohishi, T.; Kishimoto, Y.; Miura, N.; Shiota, G.; Kohri, T.; Hara, Y.; Hasegawa, J.; Isemura, M. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett. 2002, 177, 49-56.
202. Shirakami, Y.; Shimizu, M.; Tsurumi, H.; Hara, Y.; Tanaka, T.; Moriwaki, H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol. Med. Rep. 2008, 1, 355-361.
203. Singh, N.P.; Lai, H.C. Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. Anticancer Res. 2005, 25, 4325-4331.
204. Ooi, C.C.; Good, N.M.; Williams, D.B.; Lewanowitsch, T.; Cosgrove, L.J.; Lockett, T.J.; Head, R.J. Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells. Clin. Exp. Pharmacol. Physiol. 2010, 37, 905-911.
205. Kang, S.N.; Lee, E.; Lee, M.K.; Lim, S.J. Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma. Drug Deliv. 2011, 18, 143-149.
206. Almotairy, A.R.Z.; Gandin, V.; Morrison, L.; Marzano, C.; Montagner, D.; Erxleben, A. Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid. J. Inorg. Biochem. 2017, 177, 1-7.
207. Walker, A.W.; Duncan, S.H.; Louis, P.; Flint, H.J. Phylogeny, culturing, and metagenomics of the human gut microbiota. Trends Microbiol. 2014, 22, 267-274.
208. Vital, M.; Howe, A.C.; Tiedje, J.M. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio 2014, 5, e00889.
209. Van den Abbeele, P.; Belzer, C.; Goossens, M.; Kleerebezem, M.; De Vos, W.M.; Thas, O.; De Weirdt, R.; Kerckhof, F.M.; Van de Wiele, T. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 2013, 7, 949-961.
210. Bourassa, M.W.; Alim, I.; Bultman, S.J.; Ratan, R.R. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci. Lett. 2016, 625, 56-63.